HIGHLIGHTS
- who: Isabella Sudano from the Cleveland State University, United States have published the paper: Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE), in the Journal: (JOURNAL)
- what: In the present prospective Swiss national-wide cohort study, the authors aimed to investigate the patient profile, efficacy and safety of alirocumab in patients with ASCVD and/or heFH and markedly increased LDL-C despite maximally tolerated statin therapy with or without other lipid-lowering medication used and reimbursed under routine clinical conditions. For the purpose of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.